MHRA Strengthens Warnings on Botulinum Toxin After Rare Cases of Botulism

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced improved safety warnings for all botulinum toxin type A products following reports of rare but serious cases of botulism linked to their use.

The updated guidance aims to improve awareness among healthcare professionals and patients about the potential for the toxin’s effects to spread beyond the injection site. While botulinum toxin products are widely used for both medical treatments and cosmetic procedures, the MHRA says this uncommon complication can result in iatrogenic botulism. This is a potentially life-threatening condition caused by medical treatment.

The regulator is advising anyone who has recently received botulinum toxin treatment to seek immediate medical attention if they develop symptoms such as difficulty swallowing, slurred speech, breathing problems or muscle weakness. These symptoms may appear within a few days of treatment or as late as four weeks afterwards.

To reinforce awareness, the MHRA is working with manufacturers to update product information and patient information leaflets, ensuring the risks of botulism are communicated more clearly.

Dr Alison Cave, the MHRA’s Chief Safety Officer, stressed that botulinum toxin products remain safe and effective when used correctly, but said the revised warnings serve as an important reminder that serious side effects, although very rare, can occur.

She urged both healthcare professionals and patients to recognise the symptoms of botulism and seek urgent medical care if they develop. Dr Cave also warned the public against using unlicensed products and encouraged anyone considering treatment to choose appropriately qualified practitioners.

“The MHRA continuously monitors the safety of these medicines, including side effects and emerging evidence,” she said.

The UK Health Security Agency (UKHSA) echoed the MHRA’s advice, emphasising that although botulism is uncommon, prompt diagnosis and treatment can be highly effective.

Dr Martin Bewley, Consultant in Health Protection from UKHSA said: “While botulism is a rare infection, it can be serious.

“There are effective treatments available and we recommend seeking immediate medical advice if you have had a recent treatment and are having symptoms such as difficulty swallowing.

“Contact NHS 111 (or local equivalent in Northern Ireland) for further advice and seek immediate medical attention. It is important to get checked out so you can have peace of mind and treatment if needed. Given the risks, it is also important to go to a licensed practitioner.”

According to the MHRA, the likelihood of adverse reactions may increase in certain circumstances.

These circumstances may involve patients with underlying neurological conditions, individuals with a history of swallowing difficulties or aspiration, use of higher doses of botulinum toxin and treatments carried out outside licensed indications or at unapproved injection sites.

Alongside the updated warnings, the MHRA has renewed its alert over unlicensed and counterfeit botulinum toxin products. Medicines obtained outside regulated supply chains do not meet UK safety and quality standards and may significantly increase the risk of severe complications.

The agency’s Criminal Enforcement Unit has launched several investigations following a rise in hospital admissions linked to unlicensed botulinum toxin products during the past year.

Anyone considering botulinum toxin treatment should verify that their practitioner is appropriately qualified and confirm that the product being used is authorised for use in the UK.

The MHRA is also encouraging patients and healthcare professionals to report any suspected side effects through its Yellow Card reporting scheme, helping regulators continue to monitor the safety of these widely used medicines.